{"id":619973,"date":"2026-10-23T09:27:50","date_gmt":"2026-10-23T09:27:50","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/619973\/dr-kenneth-pettine-founder-of-direct-regeneration-moves-beyond-living-cells-with-a-new-line-of-exosomebased-therapies.html"},"modified":"2026-10-23T09:27:50","modified_gmt":"2026-10-23T09:27:50","slug":"dr-kenneth-pettine-founder-of-direct-regeneration-moves-beyond-living-cells-with-a-new-line-of-exosomebased-therapies","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/619973\/dr-kenneth-pettine-founder-of-direct-regeneration-moves-beyond-living-cells-with-a-new-line-of-exosomebased-therapies.html","title":{"rendered":"Dr. Kenneth Pettine, Founder of Direct Regeneration, Moves Beyond Living Cells With a New Line of Exosome-Based Therapies"},"content":{"rendered":"
\"Dr.<\/a><\/p>\n
\n
Dr. Kenneth Pettine<\/div>\n<\/div>\n<\/div>\n
<\/div>\n

FORT COLLINS, CO – October 23, 2026 –<\/strong> Retired orthopedic spine surgeon Dr. Kenneth Pettine<\/a>, founder and CEO of Direct Regeneration, today shared the next phase of his work in regenerative medicine: a growing set of patented and patent-pending products built on cell-derived materials instead of live cells. The portfolio targets joint degeneration, chronic pain, and skin aging.<\/p>\n

From spine implants to stem cells<\/strong><\/p>\n

Dr. Pettine spent more than three decades in orthopedic surgery and has served as principal investigator on 18 FDA-regulated studies. Fifteen of those were investigational device exemption trials on non-fusion spine surgery. In 2010, he turned to a different question and led the first FDA study to test a regenerative approach as an alternative to spinal surgery. The findings appeared in the Journal of Neurosurgery<\/em> and surpassed expectations, and he went on to open his own bone marrow-derived stem cell clinic.<\/p>\n

His thinking has since shifted. Dr. Kenneth Pettine<\/a> says living cells are hard to standardize and hard to distribute, and that products made from the materials cells release could be easier to test, manufacture, and make available worldwide.<\/p>\n

A growing patent portfolio<\/strong><\/p>\n

Dr. Pettine reports holding the only two issued U.S. patents covering stem cell injections into joints and the spine, plus more than twenty applications still pending. Those filings include:<\/p>\n